Infectious Mononucleosis (Mono) Transmission: EBV Dynamics, Shedding, and Prevention

Infectious mononucleosis is caused by Epstein-Barr virus (EBV, HHV-4), a gammaherpesvirus establishing lifelong latency in B lymphocytes. Transmission dynamics are distinct from acute respiratory viruses.

Transmission Mechanics

  • Primary vehicle: Saliva (hence "kissing disease").
  • Viral shedding: High titers in oropharyngeal secretions during acute illness (10⁴–10⁶ copies/mL).
  • Secondary routes: Genital secretions (sexual transmission documented), blood transfusion (rare, screened), hematopoietic transplant.
  • Not transmitted by: Casual contact, aerosols, fomites (desiccation-sensitive enveloped virus).

Shedding Timeline & Infectivity

Phase Duration Salivary Shedding Transmission Risk
Incubation 4–6 weeks Low/undetectable Low
Acute illness 2–4 weeks Peak (high titer) Highest
Convalescence Weeks to months Declining, intermittent Moderate → low
Latency (asymptomatic) Lifelong Intermittent reactivation Low but non-zero

Asymptomatic Reactivation & Transmission

  • 15–25% of seropositive adults shed EBV in saliva at any time.
  • Triggers: Stress, immunosuppression, hormonal changes, other infections.
  • Asymptomatic shedding → transmission to seronegative partners possible.
  • Most adults (90–95%) are already seropositive → reinfection not disease-causing.

Clinical Presentation Spectrum

  • Classic mono (adolescents/young adults): Fever, pharyngitis, lymphadenopathy, fatigue, splenomegaly, atypical lymphocytosis.
  • Children: Often asymptomatic or mild URI.
  • Older adults: Atypical; less pharyngitis, more hepatic involvement, prolonged fatigue.
  • Complications: Splenic rupture (0.1–0.5%), airway obstruction, hepatitis, neurologic (GBS, encephalitis), hematologic (AIHA, thrombocytopenia).

Prevention & Partner Guidance

  • During acute illness: Avoid kissing, sharing cups/utensils/toothbrushes.
  • Sexual transmission: Condoms reduce but don't eliminate (saliva contact during intimacy).
  • No vaccine available (candidates in trials; gp350 subunit).
  • Partner counseling: Most adults immune; if partner seronegative, delay intimate contact until symptoms resolve + 2 weeks.
  • Sports clearance: No contact sports × 3–4 weeks (splenic rupture risk); ultrasound not routine for clearance.

Diagnosis

  • Heterophile antibody (Monospot): 85% sensitive, 95% specific; false neg <15y, >60y.
  • EBV-specific serology: VCA-IgM (acute), VCA-IgG (past), EBNA-IgG (past >3–6 mo).
  • EBV PCR: Quantitative; not routine for diagnosis; used in transplant/immunocompromised.

Prescription Medications - Related Articles